nach oben

Erschienen in:

04.12.2017 | Original Article

Antiphospholipid antibodies, steroid dose, arterial hypertension, relapses, and late-onset predict organ damage in a population of Colombian patients with systemic lupus erythematosus

verfasst von: Luis F Pinto-Peñaranda, C. Muñoz-Grajales, A. F. Echeverri Garcia, C. J. Velásquez-Franco, M. A. Mesa-Navas, M. Zuluaga Quintero, S. Herrera-Uribe, J. D. Márquez-Hernández

Erschienen in: Clinical Rheumatology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Organ damage predicts mortality, increased accrual of detriment, and poor quality of life in systemic lupus erythematosus patients. The objective of this study is to determine the damage-free survival and its predictive factors in a population of Colombian subjects. The method used in this study is the retrospective follow-up of a cohort; damage was measured with SLICC/ACR index. Predictors of impairment were assessed by logistic regression and survival analysis. One hundred sixty-one individuals were included; 28.9% suffered damage, primarily neuropsychiatric, renal, and vascular. Arterial hypertension, antiphospholipid antibodies, prednisone dose, and number of relapses were all predictors of detriment. Onset after age 50 and daily prednisone dose higher than 7.5 mg determined earlier occurrence of damage.

Uribe A, McGwin G Jr, Reveille J, Alarc or n GS (2004) What have we learned from a 10-year experience with LUMINA (lupus in Minories nature versus nurture) cohort? Autoimmun Rev 3(4):321–329CrossRefPubMed

Cheg M, Chiew HJ, Liu Y, Ho RC (2012) Global trend of survival and damage of systemic lupus erytematosus: meta-analysis and meta-regression of observational studies from 1950 to 2000. Without Arthritis Rheum 41(6):830–839

Urowitz MB, Gladman DD, Tom BD, Iba ñ and z D, Farewell VT (2008) Changing patterns in mortality and disease outcomes for patients with systemiclupus erythematosus. J Rheumatol 35:2152–2158CrossRefPubMed

Moss KE, Ioannaou And SM Sultan, HAQ I, Isenberg D. (2002) Outcome in a cohort of 300 patients with systemic lupus erythematosus attending todedicate clinic for ever two decades. Ann Rheum Dis 61(5):409–413

Doria A, Iaccarino L, Ghirardello A et al (2006) Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 119:700–706CrossRefPubMed

Wang C, May NE, Fortin PR (2001) The relationship between health related quality of life and disease activity and damage in lupus erythematosussistemkic. J Rheumatol 28(3):525–532PubMed

Hanly JG (1997) Disease activity, cumulative damage and quality of life in systemic lupus erythematosus: result of a cross-sectional study. Lupus 6(2):243–247 57CrossRefPubMed

Nossent J, Cikes N, Kiss E, Marchesoni A (2007) Current causes of death in systemic lupus erythematosus in Europe 2000–2004: relation to disease activity and damage accrual. Lupus 16(5):309–317CrossRefPubMed

Chambers SI, Allen E, Rahman A, Isenberg D (2009) Damage and mortality in a group of British patients with systemic lupus erythematosus followed up to ten years. Rheumatology 48(6):673–675CrossRefPubMed

10.

Rhaman P, Gladman DD, Urowitz MB, Hallet D, Tan LS (2001) Early damage as measured by SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 10(2):93–96CrossRef

11.

Yee CS, Hussein H, Skan J, Bowman S, Situnsayake D, Gordon C (2003) Association of damage with antibody profile, age, race, sex and disease systemic lupus erythematosus in duration. Rheumatology 42(2):276–279CrossRefPubMed

12.

Ruiz Irastroza G, Egurvide MV, Mart í nez Berriotxoa A, Ugalde J, Aguirre C (2004) Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus 13(12):900–905CrossRef

13.

Vil to LM, Molina MJ, Mayor AM, Peredo RA, Santella ML, Vil to S (2006) Clinical and prognostic value of autoantibodies in Puerto Ricans Withsystemic lupus erythematosus. Lupus 15(12):892–898CrossRef

14.

Ugarte-Gil M, Acevedo-V to squez E, Alarc or n GS, Pastor-Asurza CA, Alfaro-Lozano JL, Cucho-Venegas JM et al. The number of flares patients experience impacts on damage systemic lupus erythematosus accrual in: data from a multiethnic Latin American cohort. Ann Rheum Dis 2015; 74(6): 1019–1023.

15.

Conti F, Ceccarelli F, Perricone C, Leccese I, Massaro L, Pacucci VA et al (2016) The Chronic systemic lupus erythematosus damage is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort. Lupus 25(7):719–726CrossRefPubMed

16.

Shinjo S, Bonfa E, Wojdyla D, Borba E, Ramirez LA, Scherbarth H et al (2010) Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 62(3):855–862CrossRefPubMed

17.

Maddison P, Farewell P, Isenberg D, Aranow C, Bae SC, Barr S et al (2002) The rate and pattern of organ damage in lateral onset systemic lupus erythematosus. J Rheum 29(5):913–917PubMed

18.

Toloza SM, Roseman JM, Alarc or n GS, McGwin G, Uriube SA, Fessler B et al (2004) Systemic lupus erythematosus in a multiethnic US cohort(LUMINA): XXII. Predictors of time to occurrence of initial damage. Arthritis Rheum 50(10):3177–3186CrossRefPubMed

19.

Nossent J, Rozman B, Pokorny G, Vlachoyiannopoulos P, Olessinka M, Marchesoni A et al (2010) Disease activity and damage accrual during the early course in a multinational inception cohort of patient with systemic lupus erythematosus. Lupus 19(8):949–956CrossRefPubMed

20.

Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Austin A, Bell A et al (1992) Derivation of the SLEDAI. A disease activity index patients for lupus. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630–640CrossRefPubMed

21.

Gladman D, Ginzler E, Goldsmith C et al (1992) Systemic lupus international collaborative clinics: development of a damage systemic lupuserythematosus in index. J Rheumatol 19(3):1820–1821PubMed

22.

Bandeira M, Buratti S, Bartoli M, Gasparini C, Breda L, Pistorio A et al (2006) Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile—onset systemic lupus erythematosus. Lupus 15(8):515–520CrossRefPubMed

23.

Reveille J, Bartolucci A, Alarcon GS (1990) Prognosis in systemic lupus erythematosus. Negative impact of increasing age onset, black race and thromobocytopenia as well as causes of death. Arthritis Rheum 33(1):37–48CrossRefPubMed

24.

Urowitz MB, Gladman DD, Iba ñ ez D, Fortin S, Bae SC, Gordon C et al (2012) Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) 64(17):132–137CrossRef

25.

Gladman DD, Urowitz MB, Rhaman P, Ib ez aN D, Tam LS (2003) Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 30(9):1955–1599PubMed

26.

Stoll T, Seifert B, Isenberg DA (1996) SLICC/ACR damage index is valid and renal and pulmonary organ score are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 35(3):248–254CrossRefPubMed

27.

Cassano G, Roverano S, Patras S, Bellomio V, Lucero E, Berman A et al (2007) Accrual of organ damage patients over time in Argentina with systemic lupus erythematosus: a multi-centre study. Clin Rheum 26(12):2017–2022CrossRef

28.

Nossent JC (1998) SLICC/ACR damage index in African-Caribbean patients with systemic lupus erythematosu: changes and relationship to disease activity, corticosteroid therapy and prognosis. J Rheumatol 25(4):654–659PubMed

29.

Ruiz Arruza I, Ugarte A, Cabezas Rodriguez I, Medina J, Moran M, Ruiz-Irastorza G (2014) Glucocorticoids and irreversible damage in systemic lupus erythematosus. Rheumatology 53(8):1470–1476CrossRefPubMed

30.

Zonana-Nacach A, Barr SD, Magder LS, Petri MA (2000) Systemic lupus erythematosus in damage and its association with corticosteroids. ArthritisRheum 43(8):1801–1808CrossRef

31.

Petri M (1995) Musculoskeletal complications of systemic lupus erythematosus in the John Hopkins lupus cohort: an update. Arthritis Care Res 8(1):137–145CrossRefPubMed

32.

Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM (2002) Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict illness damage. Arthritis Rheum 46(2):436–444CrossRefPubMed

33.

Mikdashi J, Handwerger B (2004) Predictors of neuropsychiatric systemic lupus erythematosus in damage: data from the Maryland lupus cohort. Rheumatology 43(12):1555–1560CrossRefPubMed

34.

Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C (2004) High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with lupus erythematosus systemic. Arch Int Med 164(1):77–82CrossRef

35.

Stoll T, Sutclife N, Mach J, Klaghofer R, Isenberg DA (2004) Analysis of the relationship between disease activity and damage in patients with lupuserythematosus systemic—a 5 year prospective study. Rheumatology 43(8):1039–1044CrossRefPubMed

36.

Ugarte-Gil M, Acevedo-V to squez E, Alarc or n GS, Pastor-Asurza CA, Alfaro-Alfaro-Lozano JL, Cucho-Venegas JM et al. The number of flares patients experience impacts on damage systemic lupus erythematosus accrual in: data from a multiethnic Latin American cohort. Ann Rheum Dis 2015; 74 (6): 1019–1023.

37.

Appenzeller S, Pereira DA, Costallat LTL (2008) Greater accrual damage in lateral onset systemic lupus erythematosus: a long-term follow-up study. Lupus 17(11):1023–1028CrossRefPubMed

38.

Catoggio LJ, Soriano ER, Imamura PM, Wojdyla D, Jacobelli S, Massardo L et al (2015) Lateral onset systemic lupus erythematosus in Latin-Americans: a distinct subgroup? Lupus 24(8):788–795CrossRefPubMed

39.

Bertoli AM, Alarcon GS, Calvo-Al Appen J, Fernandez to M, Vil to LM, Reveille JD, LUMINA study group (2006) Systemic lupus erythematosus in a multiethnic US cohort. Arthritis Rheum 54(5):1580–1587CrossRefPubMed

40.

Thaner M, Hern to n MA, Zhang Y, Cotter D, Petri MA (2009) Prednisone, lupus activity and permanent organ damage. J Rheumatol 36(3):560–564CrossRef

41.

Santos MJ, Vinegar F, Nero P, Barcelos F, Barcelos A, Rodrigues A et al (2009) Predictors of damage progression in Portuguese patients with systemic lupus their erythematosus. Ann N Y Acad Sci 1173(1):822–828CrossRefPubMed

42.

Estévez-Del Toro M, Chico-Capote A, Hechavarría H, Jiménez-Paneque R, Kokuina E (2010) Daño en pacientes cubanos con lupus eritematoso sistémico: relación con características de la enfermedad. Reumatol Clin 6(1):11–15

Titel: Antiphospholipid antibodies, steroid dose, arterial hypertension, relapses, and late-onset predict organ damage in a population of Colombian patients with systemic lupus erythematosus
verfasst von: Luis F Pinto-Peñaranda
C. Muñoz-Grajales
A. F. Echeverri Garcia
C. J. Velásquez-Franco
M. A. Mesa-Navas
M. Zuluaga Quintero
S. Herrera-Uribe
J. D. Márquez-Hernández
Publikationsdatum: 04.12.2017
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 4/2018
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-017-3927-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Antiphospholipid antibodies, steroid dose, arterial hypertension, relapses, and late-onset predict organ damage in a population of Colombian patients with systemic lupus erythematosus

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Malnutrition and sarcopenia in a large cohort of patients with systemic sclerosis

Clinical characteristics of autoimmune rheumatic disease-related organizing pneumonia

Comparison of composite indices with global synovitis score on ultrasound for detecting remission

Correction to: Tubulointerstitial nephritis-induced hypophosphatemic osteomalacia in Sjögren’s syndrome: a case report and review of the literature

Anti-fibrotic nintedanib—a new opportunity for systemic sclerosis patients?

Inflammatory tenosynovitis and enthesitis induced by immune checkpoint inhibitor treatment

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin